AU2023200929B2 — Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
Assigned to Apellis Pharmaceuticals Inc · Expires 2024-12-12 · 1y expired
What this patent protects
In some aspects, thepresent invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, theinvention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement mediated diso…
USPTO Abstract
In some aspects, thepresent invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, theinvention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.